RMD

ResMed
D

RMD

Arincen97/100B

ResMed balance sheet 1993–2027

ResMed had 1.01B USD in cash and short-term investments on 30 September 2026, against total debt of 610.58M USD: net cash of 400.16M USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q1 FY2027
FY2026
30 Jun 2026
FY2025
30 Jun 2025
FY2024
30 Jun 2024
FY2023
30 Jun 2023
FY2022
30 Jun 2022
FY2021
30 Jun 2021
FY2020
30 Jun 2020
FY2019
30 Jun 2019
FY2018
30 Jun 2018
FY2017
30 Jun 2017
Cash and equivalents
1.01B1.47B1.21B238.36M227.89M273.71M295.28M463.16M147.13M188.70M821.94M
Short-term investments
0.000.000.000.000.000.000.000.000.000.000.00
1.01B1.47B1.21B238.36M227.89M273.71M295.28M463.16M147.13M188.70M821.94M
Cash growth
-26.96%+21.48%+407.40%+4.59%-16.74%-7.30%-36.25%+214.80%-22.03%-77.04%+12.37%
Receivables
972.50M1.04B990.67M837.28M704.91M575.95M625.19M474.64M528.48M483.68M450.53M
Inventory
1.02B945.81M927.71M822.25M998.01M743.91M457.03M416.92M349.64M268.70M268.32M
Other current assets
443.10M457.39M164.50M180.01M179.93M131.27M124.85M75.26M0.000.000.00
Total current assets
3.51B4.32B3.51B2.36B2.37B1.93B1.57B1.52B1.15B1.07B1.64B
Property, plant and equipment
798.48M735.00M718.29M699.15M665.81M630.50M592.07M535.68M387.46M386.55M394.24M
Long-term investments
0.000.0085.03M169.77M156.89M67.22M75.45M51.10M56.70M41.23M38.32M
Goodwill and intangibles
3.35B3.36B3.51B3.33B3.32B2.28B2.32B2.34B2.38B1.28B1.33B
Goodwill
2.91B3.36B3.05B2.84B2.77B1.94B1.93B1.89B1.86B1.07B1.06B
Intangible assets
442.68M—464.86M485.90M552.34M345.94M392.58M448.17M521.95M215.18M261.80M
Other non-current assets
208.66M0.00100.81M114.24M105.56M104.53M85.46M97.58M94.28M232.48M3.74M
Total assets
8.21B8.97B8.17B6.87B6.75B5.10B4.73B4.59B4.11B3.06B3.47B
Accounts payable
320.68M308.92M278.16M237.73M150.76M159.25M138.01M135.79M115.73M92.72M92.76M
Deferred revenue
171.65M162.91M166.03M152.55M138.07M108.67M109.61M98.62M88.67M60.83M51.92M
Short-term debt
159.98M259.95M9.90M9.90M9.90M9.92M12.00M11.99M11.99M11.47M0.00
Other current liabilities
160.23M41.16M2.70M4.65M9.56M1.95M0.000.00244.00K2.37M460.00K
Total current liabilities
1.32B1.40B1.02B910.66M758.53M689.30M911.77M602.76M555.99M511.25M360.13M
Long-term debt
249.63M399.42M658.39M697.31M1.43B765.33M643.35M1.16B1.26B269.99M1.08B
Other non-current liabilities
283.97M213.03M141.52M42.26M105.35M54.86M69.74M121.26M128.11M139.03M2.43M
Lease obligations, current
31.53M29.14M30.51M25.28M21.92M21.86M23.59M21.26M0.000.000.00
Lease obligations, long-term
169.45M137.41M153.02M141.44M116.85M120.45M114.78M101.88M0.000.000.00
Total liabilities
2.26B2.38B2.21B2.01B2.62B1.74B1.84B2.09B2.04B1.00B1.51B
Common stock and paid-in capital
764.00K764.00K761.00K588.00K588.00K586.00K583.00K580.00K575.00K571.00K569.00K
Retained earnings
7.58B7.26B6.08B4.99B4.25B3.61B3.08B2.83B2.44B2.43B2.32B
Accumulated other comprehensive income
-131.74M-82.52M-74.70M-251.53M-272.53M-312.75M-193.49M-283.98M-253.01M-224.33M-189.06M
Shareholders' equity
5.95B6.59B5.97B4.86B4.13B3.36B2.89B2.50B2.07B2.06B1.96B
Minority interest
0.000.000.000.000.000.000.000.000.000.000.00
610.58M825.92M851.81M873.94M1.58B917.55M793.72M1.30B1.27B281.45M1.08B
Net cash
400.16M643.32M357.64M-635.57M-1.35B-643.84M-498.44M-836.11M-1.12B-92.75M-256.68M
Working capital
2.18B2.93B2.49B1.45B1.61B1.24B662.99M920.70M589.38M554.47M1.28B
Book value per share
41.4745.4240.5032.9728.0122.8619.7017.1414.3414.3013.76
Tangible book value
2.60B3.22B2.46B1.54B807.26M1.08B565.20M158.54M-306.21M774.85M633.59M
Tangible book value per share
18.1122.2316.6710.415.477.333.861.09-2.125.384.45
Current ratio
2.653.103.442.593.122.801.732.532.062.084.57
Debt to equity
0.100.130.140.180.380.270.280.520.610.140.55

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about ResMed's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.